Showing results (411-420 of 771) with videos related to
Sort By:
Pageof 78
Journal of Psychosomatic Research|July 18, 2017
Determinants and incidence of depression in multiple sclerosis: A prospective cohort studyS A Berzins, A G Bulloch, J M Burton, et al.Journal of Affective Disorders|July 24, 2026
"Hot" and "cold" executive functioning in currently, remitted and never depressed individualsLeanne Quigley, Stephen J M Perkovic, Eli Silverman-Lloyd, et al.Physical Review Letters|December 18, 2002
Electronic interactions in the expanded metal compound Li-NH3C A Burns, P Giura, A Said, et al.Rheumatology Advances in Practice|August 22, 2019
Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label studyJohn D Isaacs, Abdelrazig Salih, Thomas Sheeran, et al.The American Journal of Medicine|November 6, 2024
Diabetic Cardiomyopathy: What Clinicians Should KnowHannah Smati, Yusuf Kamran Qadeer, Mario Rodriguez, et al.RMD Open|February 17, 2024
Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritisPhilip M Brown, Amy E Anderson, Najib Naamane, et al.Arthritis and Rheumatism|October 11, 2001
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopeniaJ D Isaacs, S Greer, S Sharma, et al.Human Molecular Genetics|May 25, 2002
Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancerInge Søkilde Pedersen, Peter Dervan, Alo McGoldrick, et al.Annals of the Rheumatic Diseases|May 7, 2010
Profound invariant natural killer T-cell deficiency in inflammatory arthritisSusan J Tudhope, Alexei von Delwig, Jane Falconer, et al.Arthritis and Rheumatism|February 2, 2008
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomesAlice R Lorenzi, Alexandra M Clarke, Tom Wooldridge, et al.Pageof 78